OncoMatch/Clinical Trials/NCT06932471
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Is NCT06932471 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies MY008211A tablets for paroxysmal nocturnal hemoglobinuria.
Treatment: MY008211A tablets — The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Must have received: anti-C5 antibody
Stable regimen of anti-C5 antibody treatment for at least 6 months before treatment
Cannot have received: bone marrow or hematopoietic stem cell transplantation
Previous bone marrow or hematopoietic stem cell transplantation
Cannot have received: splenectomy
Previous splenectomy
Lab requirements
Blood counts
reticulocytes ≥100x10^9/l; platelets ≥30x10^9/l; neutrophils ≥0.5x10^9/l
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06932471 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bone marrow or hematopoietic stem cell transplantation, splenectomy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify